Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The continual reassessment method for dose-finding studies: a tutorial.

Elizabeth Garrett-Mayer1

  • 1Division of Oncology Biostatistics, Johns Hopkins University, Baltimore, MD, USA. esg@jhu.edu

Clinical Trials (London, England)
|March 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026
Same author

Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026
Same author

Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2025
Same author

Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America.

JCO oncology practice·2025
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Adaptive trial design and interim decision-making using incomplete longitudinal measurements: Methods and application to myasthenia gravis.

Clinical trials (London, England)·2026
Same journal

Covariate adjustment in randomized clinical trials: From general theory to practical insights.

Clinical trials (London, England)·2026
Same journal

Estimating clinical trial hazard functions.

Clinical trials (London, England)·2026
See all related articles

The Continual Reassessment Method (CRM) offers a safer and more accurate approach to dose-finding studies compared to standard designs. This tutorial provides practical guidance for implementing CRM, aiming to increase its clinical trial utilization.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacology

Background:

  • Adaptive dose-finding designs like the Continual Reassessment Method (CRM) are increasingly popular.
  • CRM offers advantages over standard Phase I designs, including fewer toxic events and more accurate maximum tolerated dose (MTD) estimation.
  • Despite its benefits, practical implementation guidance for CRM is lacking, hindering wider adoption.

Purpose of the Study:

  • To provide a practical tutorial on the Continual Reassessment Method (CRM) for statisticians and investigators.
  • To explain the specifications and variations of CRM designs.
  • To illustrate CRM implementation with simulated examples.

Main Methods:

  • Review of the original Continual Reassessment Method (CRM).

Related Experiment Videos

  • Discussion of modified CRM designs.
  • Explanation of CRM design specifications.
  • Simulation of CRM and standard dose-escalation designs for comparison.

    • Main Results:

    • The paper details the original CRM and its variations.
    • Specifications for defining a CRM design are presented.
    • Simulated examples demonstrate CRM's application and compare it to standard methods.

    Conclusions:

    • The Continual Reassessment Method (CRM) is a valuable tool for dose-finding studies.
    • Practical guidance and examples are provided to facilitate CRM implementation.
    • Increased utilization of CRM in clinical trials is anticipated.